Coherus BioSciences To Report Fourth Quarter And Full Year 2017 Financial Results On March 8th

REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018.  At 4:30 p.m. Eastern Time, Coherus' management will host a conference call to discuss the financial results and provide a general business update.  

After releasing fourth quarter and full year 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.

Conference Call InformationWhen: Thursday, March 8, 2018 at 4:30 p.m. ETDial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International) Conference ID: 7098068Webcast:  http://investors.coherus.com Please join the conference call at least 10 minutes early to register.  The webcast will be archived on the Coherus website.

About Coherus BioSciences, Inc.Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis.  For additional information, please visit www.coherus.com.

CONTACT:Patrick O'BrienSenior Vice President, Investor RelationsCoherus BioSciences, Inc. pobrien@coherus.com+1 (650) 649-3527

Primary Logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX